Uutisia, analyysejä ja markkinakalenteri

Nasdaq
		

CrownBios Integrated Oncology Platform Helps Advance Apogenixs Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

08:00 Crown Bioscience Inc. Press release CrownBios Integrated Oncology Platform Helps Advance Apogenixs Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer SANTA CLARA, Calif., 2017-09-13 23:32 CEST (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that their integrated oncology platform has facilitated the preclinical development of a HERA-GITRL immunotherapeutic from Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Cancer. The data derived from studies using CrownBios portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data showed the immunotherapys potential clinical utility and demonstrated the benefits of using CrownBios platform in preclinical efficacy testing. CrownBios integrated oncology platform confirmed our agents efficacy in NSCLC and head and neck cancers, said Dr. Mauricio Redondo Mller, Director, Preclinical Development at Apogenix. The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage. It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research, said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area. About Crown Bioscience Inc. Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. About Apogenix Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany. Media Enquiries: Jody Barbeau Crown Bioscience Inc. marketing@crownbio.com © Nasdaq
Nordnetissä voit säästää ja sijoittaa osakkeisiin, rahastoihin, ETF:iin ja muihin tuotteisiin. Ilman kiinteitä kustannuksia ja edulliseen hintaan.

Rahoitusvälineiden arvo voi nousta tai laskea. On olemassa riski, ettet saa sijoittamiasi varoja takaisin. Historiallinen kehitys ei ole tae tulevasta tuotosta. Sinun tulee perehtyä rahastoesitteeseen ja avaintietoesitteeseen ennen kuin sijoitat rahastoihin. Rahastoesitteen saat rahastoyhtiöltä ja avaintietoesitteen löydät nordnet.fi-sivustolta rahaston yleiskatsaus -sivulta sekä toimeksiantosivulta.